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A B S T R A C T
Chronic neuroinﬂammation is a hallmark of the onset and progression of brain proteinopathies such as Alzheimer disease (AD) and it is suspected to participate in the
neurodegenerative process. Transcription factor NRF2, a master regulator of redox homeostasis, controls acute inﬂammation but its relevance in low-grade chronic
inﬂammation of AD is inconclusive due to lack of good mouse models. We have addressed this question in a transgenic mouse that combines amyloidopathy and
tauopathy with either wild type (AT-NRF2-WT) or NRF2-deﬁciency (AT-NRF2-KO). AT-NRF2-WT mice died prematurely, at around 14 months of age, due to motor
deﬁcits and a terminal spinal deformity but AT-NRF2-KO mice died roughly 2 months earlier. NRF2-deﬁciency correlated with exacerbated astrogliosis and mi-
crogliosis, as determined by an increase in GFAP, IBA1 and CD11b levels. The immunomodulatory molecule dimethyl fumarate (DMF), a drug already used for the
treatment of multiple sclerosis whose main target is accepted to be NRF2, was tested in this preclinical model. Daily oral gavage of DMF during six weeks reduced
glial and inﬂammatory markers and improved cognition and motor complications in the AT-NRF2-WT mice compared with the vehicle-treated animals. This study
demonstrates the relevance of the inﬂammatory response in experimental AD, tightly regulated by NRF2 activity, and provides a new strategy to ﬁght AD.
1. Introduction
Low-grade chronic neuroinﬂammation is present at the onset and
progression of all neurodegenerative diseases involving cognitive deﬁ-
cits, motor disturbance or both. The progressive deterioration of the
brain parenchyma due to the loss of homeostatic capacity, either during
ageing, trauma, or accumulation of toxic proteins or metabolites, leads
to the release of damage-associated molecular patterns that elicit an
inﬂammatory response. Far from solving the problem, this low-level but
persistent activation of the immune system also participates in brain
damage. Therefore, a new approach towards a brain protective therapy
must consider the restoration of homeostatic functions including con-
trol of undesirable inﬂammation. Although numerous studies have
addressed the use of anti-inﬂammatory therapy to alleviate neurode-
generation [1,2], the fact is that standard non-steroidal anti-in-
ﬂammatory drugs, generally designed to stop acute inﬂammation, have
yielded mixed or inconclusive results [3–8].
In recent years, transcription factor NRF2 (Nuclear factor-erythroid
2-related factor 2) has been identiﬁed as a regulator of the extent and
duration of inﬂammatory responses [9–11]. While it is widely reported
that NRF2 regulates oxidant metabolism and several cytoprotective
responses, it is now being recognized that it also exerts immune reg-
ulatory functions by inducing the expression of anti-inﬂammatory
genes such as CD36, MARCO or IL17D [12–14] and repressing the ex-
pression of the pro-inﬂammatory genes IL6 and IL1β [15]. Additional
mechanisms involve the control of reactive oxygen species (ROS) levels,
which regulate the NF-κB response [16–18], or inhibition of the in-
ﬁltration of immune cells through the control of VCAM and MMP9
expression [19–21].
The transcriptional activity of NRF2 declines with aging [22,23], in
parallel to the dysregulation of the immune response and progression of
neuropathological hallmarks [24,25]. In fact, a direct link between
NRF2 and neurodegeneration is now being recognized by the ob-
servation that functional haplotypes of the NRF2-coding gene
(NFE2L2), that result in higher NRF2 levels are associated with pro-
tection against PD [26] while other haplotypes that result in a slight
reduction in basal NRF2 protein levels are associated with increased
risk of suﬀering AD, ALS or PD [26–29]. Thus, in the case of AD, one
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haplotype allele of NFE2L2 was associated with 2 years earlier onset of
the disease [27]. The relevance of NRF2 in neuroprotection has been
analyzed mainly in transgenic mice developing amyloid beta plaques
[30,31] or tauopathy [10,32] but not both, which is actually the case of
the human pathology. These studies have only analyzed the cognitive
eﬀects and not the motor deﬁcits, which are a general hallmark of
tauopathies such as AD, Pick disease, progressive supranuclear palsy,
corticobasal degeneration, frontotemporal dementia, parkinsonism
linked to chromosome 17, etc.
The success of NRF2-targeted immune therapy has been demon-
strated in multiple sclerosis (MS). The fumaric acid ester dimethyl fu-
marate (DMF) exhibits anti-inﬂammatory and cytoprotective actions in
astrocytes by activating the NRF2-dependent production of glutathione
and activation of heme oxygenase-1 [33,34]. Although DMF has other
targets besides NRF2 [35], at least part of its beneﬁcial eﬀects are
channeled through activation of this transcription factor [36,37].
In this study we assessed the relevance of NRF2 in the inﬂammatory
response of a combined mouse model of amyloidopathy and tauopathy
that recapitulates cognitive and motor deﬁcits similar to those found in
several neurodegenerative diseases including AD. We also used chronic
administration of DMF as a potential anti-inﬂammatory drug. Our re-
sults indicate that loss of NRF2 activity critically worsens the in-
ﬂammatory response to proteinopathy by anticipating onset and wor-
sening progression of neuropathological cues.
2. Material and methods
2.1. Transgenic mice
Colonies of NRF2-KO mice and NRF2-WT littermates were estab-
lished from founders kindly provided by Dr. Masayuki Yamamoto
(Tohoku University Graduate School of Medicine, Sendai, Japan) [38].
APPV717I mice (FVB/N), expressing in heterozygosis hAPP695 isoform
with the V717I mutation under the control of the Thy1 promoter, were
crossed with C57/BL6j-NRF2-WT (APP-NRF2-WT) or C57/BL6j-NRF2-
KO (APP-NRF2-KO). Similarly, TAUP301L mice (FVB/N), expressing in
homozygosis the longest isoform of protein TAU with the P301L mu-
tation (TAU 4R/2N P301L) under control of the mouse Thy1 gene
promoter, were crossed with C57/BL6j-NRF2-WT (TAU-NRF2-WT) or
C57/BL6j-NRF2-KO (TAU-NRF2-KO). APP/TAU-NRF2-WT (AT-NRF2-
WT) and APP/TAU-NRF2-KO (AT-NRF2-KO) in C57/BL6j background
were obtained by crossing the proper mice during more than eight
generations. Genotypic characterization of the APPV717I and TAUP301L
transgenic mice was described previously [39,40]. Animals were
housed at room temperature under a 12 h light-dark cycle. Food and
water was provided ad libitum. Animals were cared for according to a
protocol approved by the Ethical Committee for Research of the Au-
tonomous University of Madrid following institutional, Spanish and
European guidelines (Boletín Oﬁcial del Estado (BOE) of 18 March
1988; and 86/609/EEC, 2003/65/EC European Council Directives).
Once the experimental schedule was completed, animals were an-
esthetized with 8mg/kg ketamine and 1.2 mg/kg xylazine and perfused
with PBS. The brains were divided sagittally and the right hemispheres
were post-ﬁxed in 4% paraformaldehyde for 16 h and cryoprotected by
soaking in 30% sucrose solution in phosphate buﬀer until they sank.
The left hemispheres were rapidly dissected and frozen for biochemical
analysis. Spinal cord samples for immunohistochemistry were obtained
from perfused animals with PBS followed by 4% paraformaldehyde.
2.2. Evaluation of motor alterations
A protocol for measurement of motor alterations was used to eval-
uate hind limb clasping, ledge, gait and kyphosis [41]. Each measure
was recorded on a scale of 0–3, with a combined total of 0–12 for all
four measures. This test was performed as double-blind.
2.3. Novel object recognition test (NOR)
During the exploration phase, animals were placed into an empty
cage during 10min. Following 24 h the animals were allowed to ex-
plore two identical objects during 8min. During the test phase, 24 h
later, one of the objects was exchanged by a new object (diﬀerent shape
and color) and memory was assessed for 6min by comparing the time
spent exploring the novel object as compared with the time spent ex-
ploring the familiar object. The objects were cleaned thoroughly with
40% ethanol followed by distilled water between trials to remove ol-
factory cues. Active exploration was deﬁned as direct sniﬃng or
whisking towards the objects or direct nose contact. Climbing over the
objects was not counted as exploration. The relative exploration was
quantiﬁed by normalizing the diﬀerence between the exploration time
of the novel (Tn) and familiar object (Tf) by the total time of explora-
tion (Ttot) to calculate the NOR discrimination index: NOR index
= (Tn-Tf)/Ttot.
2.4. Analysis of mRNA levels
Total RNA extraction, reverse transcription and quantitative PCR
were done as detailed elsewhere [9]. Primer sequences are shown in
Suppl. Table S1. To ensure that equal amounts of cDNA were added to
the PCR, the housekeeping genes ActB, Gapdh and Tbp were ampliﬁed.
Data analysis was based on the ΔΔCT method with normalization of the
average data of housekeeping genes. All PCRs were performed in tri-
plicate.
2.5. Immunoblotting
Immunoblots were performed as described in [42]. Primary anti-
bodies are reported in Suppl. Table S2. Membranes were analyzed using
the appropriate peroxidase-conjugated secondary antibodies. Proteins
were detected by enhanced chemiluminescence (GE Healthcare, Buck-
inghamshire, United Kingdom).
2.6. Immunohistochemistry and immunoﬂuorescence
30 µm-thick sections from ﬁxed brains were immunostained as in-
dicated in [43]. For spinal cord immunohistochemistry, frozen 5 µm-
thick spinal cord sections were stained with the adequate primary an-
tibodies. For immunohistochemistry, the sections were subsequently
incubated in 0.05% 30–30 diaminobenzidine tetrahydrochloride
(Sigma-Aldrich) in Tris-HCl buﬀer, pH 8.0 for 25min, and then devel-
oped in the same buﬀer containing 0.003% hydrogen peroxide (Sigma-
Aldrich). The sections were mounted on gelatin-coated slides, air-dried,
and ﬁnally dehydrated in graded alcohols, cleared in xylene and cov-
erslipped. For immunoﬂuorescence, the sections were incubated with
secondary antibodies Alexa-Fluor546 or Alexa-Fluor488. Fluorescence
images were captured using appropriate ﬁlters in a Leica DMIRE2TCS
SP2 confocal microscope (Nussloch, Germany). The lasers used were Ar
488 nm for green ﬂuorescence and Ar/HeNe 543 nm for red ﬂuores-
cence.
2.7. Silver staining procedure
Sagittal series of 30-µm-thick sections were stained with FD
Neurosilver TM kit II (FD Neurotecnologies, MD, USA) following
manufacturer's instructions. The sections were dehydrated in ethanol
and mounted in DePex (Thermo Fisher Scientiﬁc, MA, USA).
2.8. Image analysis and statistics
Calculation of p-values from ANOVA one-way followed by Newman-
Keuls post-hoc test, ANOVA two-way followed by Bonferroni post-hoc
test and Student's t-test was done with GraphPad Prism 5 software. A p
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value of≤ 0.05 was considered signiﬁcant. Unless otherwise indicated,
all experiments were performed at least three times with similar results.
Values presented in the graphs are means of at least three samples.
Results are expressed as mean± SEM.
3. Results
3.1. NRF2-deﬁciency accelerates mouse death induced by the expression of
TAU P301L and APPV717I
The transgenic mice with neuronal expression of human hAPPV717I
and hTAUP301L proteins (for simplicity from now on denoted as AT)
were generated in C57/bl6 mice of wild type (AT-NRF2-WT) and Nrf2-
knockout (AT-NRF2-KO) backgrounds. Memory performance was ex-
amined according to a double-blind novel object recognition test (NOR)
in 6-months old animals. We observed an accelerated rate of cognitive
decline in AT-NRF2-KO mice compared to AT-NRF2-WT animals (Fig.
S1A). Moreover, AT-NRF2-KO mice exhibited a signiﬁcant reduction in
Nqo1, Osgin1, Gstm1, Aox1 and Sqstm1 compared to age-matched AT-
NRF2-WT mice (Fig. S1B).
The tissue distribution of total hAPPV717I and hTAUP301L proteins
(Suppl. Figs. S2B and S3B) was similar in both genetic backgrounds and
aﬀected neurons of the forebrain, including the isocortex (infragranular
layers V/VI of the entorhinal cortex, M1 and M2 motor cortex) and the
hippocampal formation (CA1, CA2, subiculum and hilum). In the
brainstem, hAPPV717I and hTAUP301L were localized in thalamus and
the vast majority of positive neurons and ﬁbers were found in the re-
ticular formation of the bulb and pons, including the pyramid of the
pontine nuclei and spinal trigeminal nuclei. There were positive neu-
rons and ﬁbers in cerebellum (deep cerebellum nuclei and granular
layer). The spinal cord showed positive neurons for hAPPV717I and
hTAUP301L expression in the anterior horns. Despite the similar dis-
tribution of hAPPV717I and hTAUP301L in both genotypes (Suppl. Fig.
S2C and S3C), we have previously reported that the AT-NRF2-KO mice
exhibit increased levels of toxic Aβ*56 and insoluble phospho-TAU
[43,44].
Kaplan-Meier survival curves indicated that the mean survival time
of AT-NRF2-WT mice was 14 months with some mice reaching 20
months. By contrast, 50% of AT-NRF2-KO mice died before the age of
12 months with hardly any survival at 14 months (Fig. 1A). These
diﬀerences were similar for males and females (Suppl. Fig. S4). This
premature death was associated with a rapid motor deterioration that
in a time-lapse of 4 weeks presented with progressive alterations in
ledge, clasping, gait and terminal kyphosis. Both mouse genotypes also
displayed abnormal clasping, with an abnormal simultaneous retraction
of both fore- and hind limbs (Fig. 1D). By the time that mice developed
kyphosis, a signiﬁcant weight loss was observed and death came in less
than one week. Fig. 1B shows representative animals with spinal cord
deformity and rigid thoracolumbar kyphosis that led to imminent
death. X-ray analysis did not reveal any evidence of vertebral or limbs
deformity that could be attributed to bone degeneration (Fig. 1C). To
quantify the motor behavior of AT-NRF2-WT vs. AT-NRF2-KO mice, we
used a standard double blind sensory-motor test [41]. This test mea-
sured the severity of ledge, clasping, gait and kyphosis on a scale of 0–3
for each parameter, where 0 value reﬂected non-aﬀection and 3 value
reﬂected high-aﬀection. As shown in Fig. 1E, AT-NRF2-WT mice ex-
hibited a progressive worsening of the motor disturbance at 11, 12 and
13 months while AT-NRF2-KO mice already had maximal plateau va-
lues from 11 months until spontaneous death or euthanized for ethical
reasons. Therefore, while both genotypes revealed extensive parallelism
in the expression pattern of hAPPV717I and hTAUP301L, AT-NRF2-KO
mice presented accelerated appearance of the terminal motor pheno-
type.
At the cerebellum, Purkinje and GABAergic neurons as well as as-
troglia and microglia were not aﬀected by the transgenes expression
(Suppl. Fig. S5). However, at the pontine reticular formation, FD
Neurosilver staining evidenced the presence of degenerating ﬁbers
(Fig. 2A) in both AT-NRF2-WT and AT-NRF2-KO mice but the number
of neurons with arginophilic inclusions was higher in the AT-NRF2-KO
mice (Fig. 2B). Taken together, these results suggest that the brainstem
neuronal circuits that control motor activity are the most vulnerable to
APP/TAU overexpression and that this toxic eﬀect is exacerbated in the
absence of NRF2.
3.2. NRF2 modulates brain glial and inﬂammatory responses
Based on the Kaplan-Meier survival curves and the motor alterations
described above, we took the age of 11 months as the most dis-
criminating time window to compare pathophenotypes of AT-NRF2-WT
and AT-NRF2-KO mice. We examined astrogliosis in hippocampi with
antibodies against glial ﬁbrillar acidic protein (GFAP).
Immunoﬂuorescence staining of CA1 layer and subiculum demon-
strated activated astrocytes in both genotypes, as determined by mor-
phology of thick cell bodies and small cytoplasmic branches.
Abolishment of NRF2 expression did not change the levels of GFAP
immunostaining or mRNA in hippocampus (Fig. 3A and C). These re-
sults are in accordance with no signiﬁcant loss of neurons at this region
in either AT-NRF2-KO or AT-NRF2-WT mice. Next, we analyzed mi-
croglial activation in hippocampi of these mice with antibodies against
Fig. 1. Death of the AT-mice occurs faster in the absence of NRF2. A, Kaplan-
Meier curves of AT-NRF2-WT (n= 269) and AT-NRF2-KO (n=209) over 3
years of observation. Statistical analysis was performed and a value of
***p < 0.001 was obtained comparing AT-NRF2-WT and AT-NRF2-KO curves.
B, pictures from the indicated genotypes illustrating terminal postures. C, X-ray
images of mice from the indicated genotypes showing the spinal deformity
termed kyphosis. D, representative images of the clasping behavior of wild type
and AT-mice when hanging from the tail. E, average score of the motor test
performed in which we analyzed ledge, clasping, gait and kyphosis. We tested
AT-NRF2-WT and AT-NRF2-KO animals at the indicated ages. Statistical ana-
lysis was performed with Student's t-test. *p < 0.5 comparing AT-NRF2-KO vs.
AT-NRF2-WT groups.
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CD11b. We found a mild increase in the number of CD11b positive
microglial cells in AT-NRF2-KO compared with AT-NRF2-WT mice
(Fig. 3B and D). This change was quantiﬁed by qRT-PCR evidencing a
modest but signiﬁcant increase in CD11b mRNA levels (Fig. 3B). We
also found higher mRNA levels of the pro-inﬂammatory markers, IL6
and NOS2 in AT-NRF2-KO vs. age-matched AT-NRF2-WT mice
(Fig. 3E).
Glial activation was also evaluated in the brainstem (Fig. 4) with
anti-GFAP or anti-IBA1 antibodies. GFAP and IBA1 staining was in-
creased in the AT-NRF2-KO mice in both locations (Fig. 4A). These
results were further conﬁrmed in immunoblots from AT-NRF2-WT and
AT-NRF2-KO brainstem lysates (Fig. 4B). GFAP and IBA1 levels were
about two-fold higher in the AT-NRF2-KO mice compared with age-
matched AT-NRF2-WT mice in brainstem samples (Fig. 4C). Similar
experiments were conducted to analyze astroglial and microglial acti-
vation in spinal cord (Fig. 5). In accordance with the results showed in
Fig. 1, macroscopic analysis of the spinal cord dissected from AT-NRF2-
KO mice evidenced higher torsion angle compared with AT-NRF2-WT.
In line with the results obtained in brainstem, NRF2-deﬁciency led to
increased staining of GFAP and IBA1 in white and grey matter of the
spinal cord (Fig. 5A). Then, we conﬁrmed these observations in im-
munoblots from AT-NRF2-WT and AT-NRF2-KO spinal cords samples.
The protein levels of GFAP and IBA1 were slightly increased in the AT-
NRF2-KO compared with AT-NRF2-WT mice (Fig. 5B and C). These
results suggest that NRF2-deﬁciency exacerbates glial activation in
these locations.
3.3. DMF reduces motor alteration and improves memory
Our next goal was to evaluate whether NRF2 activation with di-
methyl fumarate (DMF) could modulate the pathological outcomes
triggered by APP and TAU expression. In a previous study we already
established the conditions of DMF administration by oral gavage and
demonstrated that it reaches the brain and activates the NRF2 tran-
scriptional signature in this organ [45]. As shown in Suppl. Fig. S6A, 9
months-old AT-NRF2-WT mice were treated by oral gavage with vehicle
or DMF (100mg/kg) once every two days for six weeks. This age was
chosen because motor alterations and cognitive deﬁcits were still ab-
sent. During the whole time of treatment, we did not detect changes in
weight that would be attributed to feeding problems after oral gavage
(Suppl. Fig. S6B). Five days after the ﬁrst administration, animals were
weighted and submitted to double-blind motor and novel object re-
cognition (NOR) tests to obtain baseline values of memory. This pro-
tocol was repeated once every two weeks. As shown in Fig. 6A, mRNA
levels of NRF2-target genes were analyzed by qRT-PCR. We found a
statistically signiﬁcant increase in the expression of Nrf2, Nqo1, Osgin1,
and Gstm1 in the brain, in agreement with NRF2-activation by DMF.
Next, we evaluated astrocytosis and microgliosis employing GFAP and
IBA1 antibodies, respectively. As shown in Fig. 6B, DMF ameliorated
the levels of GFAP positive cells in hippocampus and in brainstem in-
dicating preservation of the neural tissue. Similarly, microgliosis was
also reduced in both regions of the DMF-treated mice (Fig. 6C). More-
over, in response to DMF we found a downward trend in the protein
levels of the pro-inﬂammatory mediators COX2 and NOS2, as well as
the gliosis markers GFAP, IBA1 and MHCII (Fig. 6D and E). The average
motor score slightly increased over the duration of the experiment in
the vehicle treated mice but remained unchanged in the DMF-treated
group, suggesting that NRF2 activation attenuates the progression of
the motor alterations (Fig. 6F). In parallel, we analyzed the mice ability
to discriminate a novel object in the environment. The discrimination
index of the DMF-treated group raised 2.5–3-fold compared with the
value of the vehicle-treated group, indicating a tendency to better
memory function in parallel to NRF2 activation (Fig. 6G). Although, the
diﬀerences achieved in both tests were modest, the tendency was sta-
tistically signiﬁcant at 2-weeks. Taken together, these results indicate
that NRF2 activation by DMF alleviates brain inﬂammation as well as
motor and cognitive disability triggered by hAPPV717I and hTAUP301L
expression.
4. Discussion
In the present study, we used a new mouse model of combined
amyloidopathy and tauopathy to analyze the eﬀect of NRF2 on neu-
roinﬂammation, which is a crucial pathological hallmark of neurode-
generative diseases such as AD. In a previous study, we employed these
mice to characterize the eﬀect of NRF2-deﬁciency in autophagy and
several pathophenotypes associated with AD [43,44]. Here we describe
the eﬀect of NRF2-deﬁciency on motor and cognitive deﬁcits, as well as
gliosis and neuroinﬂammation.
Motor alterations were produced mainly in response to tauopathy,
since they were detected even in transgenic mice expressing only the
hTAUP301L protein (data not shown and [46,47]). Motor deﬁcits are
common in human tauopathies such as AD, Pick disease, progressive
supranuclear palsy, corticobasal degeneration, frontotemporal de-
mentia and parkinsonism linked to chromosome 17, spinocerebellar
ataxia type 11, etc. Regarding amyloidopathy, an analysis of ﬁve Han
Chinese EOFAD families with the APPV717I mutation exhibited clinical
symptoms of cerebellar ataxia. Mutations in presenilin 1 have also been
associated with cerebellum alterations and movement disorders
[48,49]. However, although we detected a modest expression of APP
and TAU protein in cerebellar regions, we did not appreciate any al-
teration in Purkinje, GABAergic or glial cells that could explain motor
disturbance (Supl. Fig. S5). Most likely, motor alterations were related
Fig. 2. Neurodegeneration in the brainstem was exacerbated in the absence of
NRF2. A and B, silver staining of sagittal brain sections from 11-months old
mice of the indicated genotypes. Pictures show dystrophic neurites (A) and
neurons with arginophilic inclusions (B) in the pontine reticular formation. C,
quantiﬁcation of the number of positive neurons with arginophilic inclusions
from B. Data are mean± SEM (n=3). Statistical analysis was performed with
Student's t-test. *p < 0.05, comparing AT-NRF2-KO vs. AT-NRF2-WT groups.
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to the damage to somatomotor neurons located at the nuclei of the
brainstem and the anterior horn of the spinal cord. In these regions, we
detected exacerbated microgliosis and astrogliosis and spheroid axons
[44]. Previous studies with hTAUP301L expressing mice in a Swiss/3T3
genetic background under the control of either the prion or the Thy1
promoter demonstrated a role of progressive tauopathy in the alteration
of brainstem nuclei, leading to motor alterations similar to those
described here [50–52]. However, our C57/Bl6 mice lived several
months longer than the Swiss/3T3 mice, thus suggesting strain speciﬁc
properties. Independent studies have correlated the motor deﬁcits ob-
served in AT-mice with TAUP301L overexpression [46,47] as well as
with redox imbalance [53]. Our observations extended the impact,
because we directly connected TAU pathology with redox, in-
ﬂammatory and proteostasis stress through NRF2-deﬁciency.
Fig. 3. Gliosis is exacerbated by NRF2 deﬁciency in hippo-
campi of AT-NRF2-KO mice. A and B, brain sections from 11-
months old AT-NRF2-WT and AT-NRF2-KO mice were stained
with GFAP or CD11b, respectively. Pictures show CA1 and
subiculum regions of the hippocampus. C and E, mRNA levels
determined by qRT-PCR of the indicated genes normalized to
the expression of ActB. Data are mean± SEM (n=4).
Statistical analysis was performed with Student's t-test.
*p < 0.05, comparing AT-NRF2-KO vs. AT-NRF2-WT mice.
D, number of CD11b-positive microglial cells in CA1 and
subiculum of the indicated genotypes. Data are mean± SEM
(n=3) represented as % of the total number of cells.
Statistical analysis was performed with Student's t-test.
*p < 0.05, comparing AT-NRF2-KO vs. AT-NRF2-WT mice.
Fig. 4. Increased glial activation in the brain-
stem of AT-NRF2-KO mice. A, immunostaining
with anti-GFAP and anti-IBA1 in sagittal sec-
tions of the pontine reticular formation of the
brainstem in the indicated genotypes. B, im-
munoblot analysis of GFAP and IBA1 levels in
brainstem and spinal cord homogenates from
11-month old AT-NRF2-WT and AT-NRF2-KO
mice. Protein levels of GAPDH were analyzed
to ensure similar load per lane. C, densito-
metric quantiﬁcation of representative blots
from B. Data are mean± SEM (n=3).
Statistical analysis was performed with
Student's t-test. *p < 0.05, comparing AT-
NRF2-KO vs. AT-NRF2-WT mice.
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The anatomopathological and clinical phenotype of terminal AT-
NRF2-KO mice could not be distinguished from terminal AT-NRF2-WT
mice. However, the pathology spread over a narrower age-window
when NRF2 was absent: 12 months in AT-NRF2-KO mice as opposed to
14 months in AT-NRF2-WT mice. The AT-NRF2-KO mice recapitulate
the main AD hallmarks including loss of redoxtasis and proteostasis
[31,32,43,44] and, as described here, the presence of neuroinﬂamma-
tion. Our previous results strongly support that NRF2-deﬁciency mimics
transcriptomic features found in AD brains [44]. It is therefore rea-
sonable to speculate that neurons should be more susceptible to APP
and TAU toxicity in the NRF2-deﬁcient than in the wild type back-
ground. Indeed, AT-NRF2-KO mice exhibited more damaged neurons in
brainstem, exacerbated cognitive [44] and motor impairments, and
premature death.
Experimental and clinical evidence suggests that DMF plays a pro-
minent role in targeting brain inﬂammation mainly through NRF2 ac-
tivation [35,54–56]. Accordingly, we detected induction of NRF2, a
reduction of inﬂammatory markers and improvement of motor and
memory cues in the brain of 9-month old AT-NRF2-WT mice treated
with DMF. These results are in line with protective functions reported in
diverse models of neurodegenerative diseases and its eﬀects in pre-
vention of spatial memory impairment and hippocampal neurodegen-
eration mediated by intracerebroventricular injection of streptozotocin
in rats [57]. From the immunomodulatory point of view, additional
mechanisms independent of NRF2 have been proposed to explain the
therapeutic value of DMF [35,58]. We did not test NRF2-independent
eﬀects of DMF in the AT-NRF2-KO mice since as indicated in Suppl. Fig.
S4 they exhibit high mortality during the time of experimentation.
However, the fact that the DMF targeted the NRF2 transcriptional sig-
nature in the brain together with the established evidence of the im-
munomodulatory signals, points towards NRF2-dependent beneﬁcial
eﬀects of DMF. Future clinical work will be needed to deﬁnitely de-
termine if pharmacological activation of NRF2 may be a valid strategy
to ameliorate neurodegeneration but surely DMF will be a suitable
candidate because it is the only FDA- and EAE-approved NRF2 acti-
vator.
5. Conclusion
We have developed a new mouse model that combines amyloido-
pathy and tauopathy with deﬁciency in the master regulator of
homeostatic responses, the transcription factor NRF2. The study de-
monstrates that low-grade chronic neuroinﬂammation is a driver of
neurodegeneration, and not just a consequence, since an antioxidant
modulator of inﬂammation, DMF, which targets NRF2, protected from
disease progression. The fact that DMF is already in clinical use for
multiple sclerosis provides a rationale for repurposing this drug in AD.
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